UY31105A1 - Predicción pronóstica del melanoma - Google Patents

Predicción pronóstica del melanoma

Info

Publication number
UY31105A1
UY31105A1 UY31105A UY31105A UY31105A1 UY 31105 A1 UY31105 A1 UY 31105A1 UY 31105 A UY31105 A UY 31105A UY 31105 A UY31105 A UY 31105A UY 31105 A1 UY31105 A1 UY 31105A1
Authority
UY
Uruguay
Prior art keywords
markers
cancer
melanoma
forecast
prognostic
Prior art date
Application number
UY31105A
Other languages
English (en)
Inventor
John Thomas
Guilford Parry John
Cebon Jonathan
Black Michael Alan
Original Assignee
Ludwig Inst For Cancer Research
Pacific Edge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Research, Pacific Edge Biotechnology Ltd filed Critical Ludwig Inst For Cancer Research
Publication of UY31105A1 publication Critical patent/UY31105A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a marcadores pronóstico y distintivos pronósticos, así como a composiciones y a métodos para determinar el pronóstico del cáncer, en particular del melanoma, en un paciente. En particular, la invención se refiere al uso de marcadores proteínicos y genéticos para predecir el riesgo de progresión de un cáncer, como por ejemplo de un melanoma, sobre la base de marcadores y distintivos compuestos por marcadores. En diversos aspectos, la invención suministra métodos, composiciones, kits y sistemas a base de marcadores pronósticos del cáncer, en particular marcadores pronósticos del cáncer, en particular marcadores pronósticos de melanoma, para contribuir al pronóstico y tratamiento del cáncer.
UY31105A 2007-05-24 2008-05-26 Predicción pronóstica del melanoma UY31105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ555363A NZ555363A (en) 2007-05-24 2007-05-24 Prognosis prediction for melanoma cancer

Publications (1)

Publication Number Publication Date
UY31105A1 true UY31105A1 (es) 2009-01-05

Family

ID=40032133

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31105A UY31105A1 (es) 2007-05-24 2008-05-26 Predicción pronóstica del melanoma

Country Status (17)

Country Link
US (3) US8822149B2 (es)
EP (2) EP2158332B1 (es)
JP (5) JP5943315B2 (es)
CN (1) CN101743327B (es)
AR (1) AR066725A1 (es)
AU (1) AU2008253836B2 (es)
CA (1) CA2725602A1 (es)
CL (1) CL2008001517A1 (es)
DK (2) DK2158332T3 (es)
ES (2) ES2622858T3 (es)
HK (1) HK1145342A1 (es)
NZ (1) NZ555363A (es)
PT (2) PT2158332T (es)
SG (2) SG10201509568QA (es)
TW (2) TWI582236B (es)
UY (1) UY31105A1 (es)
WO (1) WO2008143533A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120135415A1 (en) * 2002-11-15 2012-05-31 Morehouse School Of Medicine Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies
PL2140269T3 (pl) 2007-03-27 2014-07-31 Immunovia Ab Podpis białkowy/znaczniki do wykrywania gruczolakoraka
JP5683280B2 (ja) * 2011-01-04 2015-03-11 株式会社日立製作所 診療支援システム
CN102617734B (zh) * 2011-12-28 2013-09-04 暨南大学 抗FGF-2抗体Dab-2及其应用
US9336302B1 (en) 2012-07-20 2016-05-10 Zuci Realty Llc Insight and algorithmic clustering for automated synthesis
US9355105B2 (en) * 2012-12-19 2016-05-31 International Business Machines Corporation Indexing of large scale patient set
ES2947946T3 (es) 2013-03-14 2023-08-24 Castle Biosciences Inc Métodos para predecir el riesgo de metástasis en melanoma cutáneo
EP3292536B1 (en) * 2015-05-05 2024-04-03 RetInSight GmbH Computerized device and method for processing image data
WO2018009887A1 (en) * 2016-07-08 2018-01-11 University Of Hawaii Joint analysis of multiple high-dimensional data using sparse matrix approximations of rank-1
US11205103B2 (en) 2016-12-09 2021-12-21 The Research Foundation for the State University Semisupervised autoencoder for sentiment analysis
US10692605B2 (en) * 2018-01-08 2020-06-23 International Business Machines Corporation Library screening for cancer probability
TW202018727A (zh) 2018-11-09 2020-05-16 財團法人工業技術研究院 整體式學習預測方法與系統
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112200391B (zh) * 2020-11-17 2023-07-04 国网陕西省电力公司经济技术研究院 基于k-近邻互信息特征简化的配电网边缘侧负荷预测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074330A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074430A2 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008043018A1 (en) * 2006-10-04 2008-04-10 Dana-Farber Cancer Institute, Inc. Tumor immunity

Also Published As

Publication number Publication date
JP2017079765A (ja) 2017-05-18
AR066725A1 (es) 2009-09-09
CL2008001517A1 (es) 2009-01-09
EP3176270B1 (en) 2020-07-08
JP2015061528A (ja) 2015-04-02
PT3176270T (pt) 2020-10-08
TWI582236B (zh) 2017-05-11
US20100136553A1 (en) 2010-06-03
NZ555363A (en) 2009-11-27
TWI609967B (zh) 2018-01-01
AU2008253836B2 (en) 2014-11-27
PT2158332T (pt) 2017-04-26
EP2158332A4 (en) 2011-01-05
EP2158332A1 (en) 2010-03-03
US8822149B2 (en) 2014-09-02
SG10201912289SA (en) 2020-02-27
SG10201509568QA (en) 2015-12-30
EP2158332B1 (en) 2017-01-18
CA2725602A1 (en) 2008-11-27
ES2821300T3 (es) 2021-04-26
US20170107583A1 (en) 2017-04-20
US20150031578A1 (en) 2015-01-29
EP3176270A1 (en) 2017-06-07
DK2158332T3 (en) 2017-05-01
ES2622858T3 (es) 2017-07-07
AU2008253836A1 (en) 2008-11-27
CN101743327A (zh) 2010-06-16
TW201500553A (zh) 2015-01-01
HK1145342A1 (en) 2011-04-15
WO2008143533A1 (en) 2008-11-27
JP2010527604A (ja) 2010-08-19
JP6404304B2 (ja) 2018-10-10
US9534258B2 (en) 2017-01-03
JP2019004907A (ja) 2019-01-17
TW200914623A (en) 2009-04-01
JP5943315B2 (ja) 2016-07-05
JP2020150949A (ja) 2020-09-24
CN101743327B (zh) 2013-04-24
DK3176270T3 (da) 2020-10-12
US10266902B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
UY31105A1 (es) Predicción pronóstica del melanoma
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
CO7160023A2 (es) Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
CY1115178T1 (el) Βιοδεικτες καρκινου
EA201171367A1 (ru) Винилиндазолильные соединения
ATE461990T1 (de) Zusammensetzung für die gewebepflege
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MX370486B (es) Composiciones, métodos y usos para asistir en el diagnóstico, pronóstico y tratamiento de la fibrosis pulmonar idiopática.
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
UA107822C2 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
BR112014032728A2 (pt) uso de marcadores no diagnóstico e tratamento de câncer de próstata
BRPI0604761A (pt) detecção de metilação de gene
CR9298A (es) Marcadores farmacogenomicos para el pronostico de tumores solidos
CL2009001363S1 (es) Pieza para maquina de afeitar.
MX2007010332A (es) Metodos y composiciones para promover adhesion o migracion de celula endotelial.
ATE525484T1 (de) Slco1b3-genotyp
ATE532814T1 (de) Neue ammonium-polyurethan- und/oder polycarbonat- verbindungen
CL2012002762A1 (es) Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit.
CY1116492T1 (el) Δραστηριοτητα του τεμσιρολιμου κατα των ογκων στον καρκινο θηλοειδων νεφρικων κυτταρων
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
BR112013009143A2 (pt) método in vitro, uso e invenção
ATE517346T1 (de) Gpr18 als biomarker für th1-vermittelte immunantwort

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20201022